Status
Conditions
About
A multicenter registry to explore the clinical outcome of Chinese adult patients with active Ankylosing Spondylitis *AS* treated with adalimumab,prescribed according to the local label,in the real world practice
Full description
This registry will be conducted in a non-interventional setting for AS patients using adalimumab in China.The primary objective is to evaluate the effectiveness and safety of adalimumab in Chinese AS patients in real world clinical practice.The secondary objective is to 1)compare the clinical outcome in patients with or without good persistence with adalimumab;2)investigate the predicting factors of a good clinical response after discontinuation of adalimumab.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
1.Patients with contraindication or are not appropriate to use adalimumab according to the local label will be excluded
400 participants in 1 patient group
Loading...
Central trial contact
Jinmei Su, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal